Sigachi Industries Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/s10kf1d6s4rfeawh4wxrh599.pdf

Key Takeaways


Top-Line Performance & Realization

Amit Raj Sinha: "We of course are seeing rising inflation. But however, we have not really seen it impacting our demand. The prime reason is that we primarily catering to the Pharmaceutical industry, which is not new so we don't see decrease in demand in any way."

Margin Structure & Sustainability

Amit Raj Sinha: "We have seen is that, at this moment we are able to pass on the increased pulp prices onto the customers. So that's a very big comfort."

Capacity Expansion & Capex Cycle

Amit Raj Sinha: "We really are not able to commit you update, but once the EC clearances in place we will definitely have a date to it because everything else is already structured in the project management team members."

New Ventures: Nutrition, OTC & Dubai

Amit Raj Sinha: "We would have little lower EBIDTA compared to our excipient lines on account of Nutritional and OTC segment in the initial phase. However, as we continue to service and continue to expand our product portfolio, we believe that we should be able to come back to our base margin of 20% EBITDA."

Competitive Positioning & Customer Profile

Amit Raj Sinha: "Their customer profiles are primarily the innovators. And historically, innovative companies have been working with the world number one. We have been trying to get into the innovative companies, but it is still work in progress..."

Ethanol Project Status

Amit Raj Sinha: "We realize that there are certain aspects of this which are of course very, very different from what we do and certain aspects which are not entirely in control of the government. So it is not that government is going to be positive about it, so at this moment we are exploring and seeing which way it aligns with our overall purpose and possibly we might actually not be going ahead..."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue CAGRMaintain the CAGR achieved over the last three yearsOngoing
MCC capacity addition7,000 MT to become operationalQ4 FY23
New capacity utilizationAchieve 60% utilization of increased capacityFY24
Jhagadia & Dahej capex completionUnspent ₹16 Crores to be fully spentBefore last quarter of FY23
EBITDA margin sustainability21–22% EBITDA margin sustainedFull year FY23 and next year
Nutrition & OTC margin recoveryReturn to base margin of 20% EBITDAAs product portfolio expands (undated)
Ethanol decisionBoard to take official go/no-go decisionIn a couple of months
CCS commissioning dateWill provide a date once EC clearance is in handAfter EC clearance (6–12 months process)
Royalty structure alignmentDo homework on aligning royalty to bottom line vs top lineUndated commitment

Key Metrics

MetricQ1 FY23
Operational revenue₹78 cr, +43% YoY
EBITDA₹16 cr, +34% YoY
EBITDA margin20.82%
Net profitNot stated
Volume growth~10% QoQ
Realization growth19% QoQ
Average selling price₹217, vs ₹182 in Q1 FY22
Export sales share75.43%, vs 73.6% in Q1 FY22
Material consumption47% of revenue, vs 51% in Q1 FY22
Total capacity>13,000 MTPA, expanding to 20,000 MTPA via ongoing capex
Capacity addition expected7,000 MTPA, in later part of FY23
Existing capacity utilization~95%
Premix facility expected FY23 revenue₹18–20 cr
Raw material price$828–$830 per metric ton average, up from $650
Employee strength900